The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2023
Filed:
Sep. 22, 2017
Applicant:
Kbp Biosciences Pte. Ltd., Jinan, CN;
Inventors:
Zhenhua Huang, Jinan, CN;
Xiaocui Guo, Jinan, CN;
Assignee:
KBP Biosciences Pte. Ltd., Singapore, SG;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4745 (2006.01); A61K 47/10 (2017.01); A61K 9/00 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61P 13/12 (2006.01); A61K 47/18 (2017.01); A61K 47/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4745 (2013.01); A61K 9/00 (2013.01); A61K 9/0053 (2013.01); A61K 47/00 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61P 13/12 (2018.01); A61K 45/06 (2013.01);
Abstract
Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.